• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by GlycoMimetics Inc. (Amendment)

    2/10/22 8:11:48 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLYC alert in real time by email
    SC 13G/A 1 tv0999-glycomimeticsinc.htm SCHEDULE 13G/A glycomimeticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  GlycoMimetics Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  38000Q102

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  38000Q102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    2,224,241

    8.  SHARED DISPOSITIVE POWER

    14,312

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,238,553

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.33%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    GlycoMimetics Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    9708 Medical Center Drive
    Rockville, MD 20850

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    38000Q102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $GLYC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLYC

    DatePrice TargetRatingAnalyst
    3/21/2025Overweight
    Cantor Fitzgerald
    7/26/2024Buy → Hold
    TD Cowen
    12/22/2023$12.00Overweight
    CapitalOne
    11/12/2021$3.00 → $4.00Hold → Buy
    Jefferies
    More analyst ratings

    $GLYC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

    —GlycoMimetics Board of Directors approves 1-for-100 reverse stock split— GlycoMimetics, Inc. (NASDAQ:GLYC) ("GlycoMimetics") today announced that its stockholders have approved the proposed merger (the "Merger") with Crescent Biopharma, Inc. ("Crescent"), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics' special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the "Special Meeting"), including a reverse stock split of GlycoMimetics' common stock to be effected at the discretion of the board of directors of GlycoMimetics (the "Board") within the parameters approved by GlycoMimetics' stockholders. On June 5, 2025, f

    6/5/25 4:01:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

    WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced that management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 5, 2025, at 11:05 a.m. ET. A live webcast of the presentation will be available at https://wsw.com/webcast/jeff319/cresc/1993344, and an archived replay will be accessible for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with GlycoMimetics, Inc. (NASDAQ:GLYC). Following c

    5/29/25 7:30:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Appoints David Lubner to Board of Directors

    Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

    4/28/25 7:30:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on GlycoMimetics

    Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight

    3/21/25 8:14:54 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics downgraded by TD Cowen

    TD Cowen downgraded GlycoMimetics from Buy to Hold

    7/26/24 7:49:13 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CapitalOne initiated coverage on GlycoMimetics with a new price target

    CapitalOne initiated coverage of GlycoMimetics with a rating of Overweight and set a new price target of $12.00

    12/22/23 7:25:28 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GLYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GLYC
    SEC Filings

    View All

    SEC Form 3 filed by new insider Im Ellie Eunkyung

    3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    6/30/25 4:21:21 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Bispham Barbara Harlin

    3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    6/30/25 4:16:25 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Moran Susan

    4 - GLYCOMIMETICS INC (0001253689) (Issuer)

    6/23/25 6:51:54 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rock Edwin bought $78,824 worth of shares (305,000 units at $0.26), increasing direct ownership by 81% to 680,403 units (SEC Form 4)

    4 - GLYCOMIMETICS INC (0001253689) (Issuer)

    6/24/24 4:29:48 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), increasing direct ownership by 33% to 70,643 units (SEC Form 4)

    4 - GLYCOMIMETICS INC (0001253689) (Issuer)

    6/20/24 4:15:39 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Rock Edwin bought $90,256 worth of shares (65,403 units at $1.38), increasing direct ownership by 21% to 375,403 units

    4 - GLYCOMIMETICS INC (0001253689) (Issuer)

    9/25/23 4:21:40 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure

    8-K - GLYCOMIMETICS INC (0001253689) (Filer)

    6/18/25 5:28:58 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - GLYCOMIMETICS INC (0001253689) (Filer)

    6/6/25 8:30:34 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by GlycoMimetics Inc.

    425 - GLYCOMIMETICS INC (0001253689) (Subject)

    5/30/25 8:30:55 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLYC
    Leadership Updates

    Live Leadership Updates

    View All

    Crescent Biopharma Appoints David Lubner to Board of Directors

    Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

    4/28/25 7:30:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

    GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w

    9/6/22 7:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

    GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p

    3/2/22 9:15:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLYC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLYC
    Financials

    Live finance-specific insights

    View All

    GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

    Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim

    10/29/24 7:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3

    6/4/24 7:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company

    5/6/24 6:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GlycoMimetics Inc.

    SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)

    11/12/24 4:30:27 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/6/24 5:41:38 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care